Samsung Biologics 2022 Net Income More than Doubles
SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday its 2022 net income more than doubled on strong overseas sales of its biomedicine products after its takeover of Samsung Bioepis Co. Its net income reached 798.1 billion won (US$648.1 million) in 2022, up 102.8 percent [...]